Sarms Powder Coluracetam for Improving Memory

Name: Coluracetam
Specification: 99%
CAS No.: 135463-81-9
Appearance: White powder
Molecular Formula: C19H23N3O3
Molecular Weight: 341.4042
Coluracetam is a nootropic drug of the racetam family. Coluracetam was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer’s disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depression disorder (MDD), after being awarded a “Qualifying Therapeutic Discovery Program Grant” by the state of California. Findings from its Phase 2a clinical trials have suggested that it would be an ideal medication for co-morbid MDD with generalized anxiety disorder (GAD). BrainCells Inc is currently out-licensing the drug for this purpose. It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.

 

Function

Enhance mental intelligence
Boost memory and leaning capabilities
Improve brain power to solve problems and protect it from any chemical or physical injury
Enhance motivation level
Enhance the control of cortical/subcortical brain mechanism
Improve sensory perception

 

Application

Coluracetam enhances high-affinity choline uptake (HACU) which is the rate-limiting step of acetylcholine (ACh) synthesis, and is the only known choline uptake enhancer to currently exist. Studies have shown Coluracetam to improve learning impairment on a single oral dose given to rats which have been exposed to cholinergic neurotoxins. Subsequent studies have shown that it may induce long-lasting procognitive effects by changing the choline transporter regulation system.
 
Coluracetam is a nootropic drug of the racetam family. Coluracetam was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer’s disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depression disorder (MDD), after being awarded a “Qualifying Therapeutic Discovery Program Grant” by the state of California. Findings from its Phase 2a clinical trials have suggested that it would be an ideal medication for co-morbid MDD with generalized anxiety disorder (GAD). BrainCells Inc is currently out-licensing the drug for this purpose. It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s